Significant agreements - Summary of Contract Assets and Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Contract liabilities:
Beginning Balance	$ 101,658	$ 135,194
Additions	960	3,386
Deductions	(70,586)	(35,275)
Impact of Exchange Rates	6,437	(1,647)
Ending Balance	38,469	101,658
Contract assets
Contract assets	0	0
Bayer collaboration deferred revenue
Contract liabilities:
Beginning Balance	39,960	43,618
Additions	960	296
Deductions	(8,920)	(3,393)
Impact of Exchange Rates	2,629	(561)
Ending Balance	34,629	39,960
Bayer collaboration deferred revenue \| Deferred revenue material rights option
Contract liabilities:
Ending Balance	31,600
Novartis collaboration deferred revenue
Contract liabilities:
Beginning Balance	44,073	50,008
Additions		3,000
Deductions	(46,985)	(8,161)
Impact of Exchange Rates	2,912	(774)
Ending Balance	0	44,073
Ionis collaboration deferred revenue
Contract liabilities:
Beginning Balance	3,587	12,464
Additions		90
Deductions		(8,881)
Impact of Exchange Rates	253	(86)
Ending Balance	3,840	3,587
Ionis collaboration deferred revenue \| Deferred revenue material rights option
Contract liabilities:
Ending Balance	3,800
Genentech collaboration deferred revenue
Contract liabilities:
Beginning Balance	14,038	29,104
Deductions	(14,681)	(14,840)
Impact of Exchange Rates	643	(226)
Ending Balance	$ 0	$ 14,038